Topotecan as single agent or in combination with carboplatin in pretreated and heavily pretreated patients with advanced ovarian cancer

被引：0

作者：

Martoni, A ^{[1
]}

Pelusi, G ^{[1
]}

De Jaco, P ^{[1
]}

Taroni, B ^{[1
]}

Cacciari, N ^{[1
]}

Angelelli, B ^{[1
]}

Marino, A ^{[1
]}

Zamagni, C ^{[1
]}

机构：

[1] S Orsola Malpighi Hosp, Div Med Oncol, Bologna, Italy

来源：

7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY | 1999年

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied the tolerability and the activity of topotecan as single agent in 19 consecutive patients with advanced ovarian cancer, pretreated with at least one platinum-based chemotherapy. We also investigated topotecan in combination with carboplatin in 7 consecutive patients with the same characteristics. No grade 3-4 nonhematologic toxicities were observed. Grade 3 and 4 neutropenia and thrombocytopenia were the most relevant side-effects, both in patients treated with topotecan alone and in patients treated with topotecan and carboplatin. An objective remission was documented in 27% of patients treated with topotecan and in 43% of patients treated with the combination regimen. Our experience confirms that topotecan is an active agent in pretreated advanced ovarian cancer patients, the limiting toxicity being represented by myelotoxicity.

引用

页码：253 / 256

页数：4

共 5 条

[1]

[Anonymous], J CLIN ONCOL

[2]

CACCIARI N, IN PRESS EUR J GYNAE

[3] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].

McGuire, WP ;

Hoskins, WJ ;

Brady, MF ;

Kucera, PR ;

Partridge, EE ;

Look, KY ;

ClarkePearson, DL ;

Davidson, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6

[4]

SCHILDER RJ, 1998, P ASCO, V17

[5]

THIGPEN T, 1999, ASCO ED BOOK, P564

← 1 →